文献速递眼底病与葡萄膜炎神经眼科

玻璃体内注射雷珠单抗对新生血管性年龄相关性黄斑变性患者神经节细胞复合体及视乳头周围视网膜神经纤维层的影响:基于频域光学相干断层扫描

EFFECT OF INTRAVITREAL RANIBIZUMAB ON GANGLION CELL COMPLEX AND PERIPAPILLARY RETINAL NERVE FIBER LAYER IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION USING SPECTRAL DOMAIN OPTICAL COHERENCE TOMOGRAPHY.
PubMed 文献 · Retina · 2017-01-01

本研究纳入24只未经治疗的新生血管性年龄相关性黄斑变性眼,接受三个月每月一次玻璃体内雷珠单抗负荷治疗后按需再治疗12个月。结果显示神经节细胞复合体和视乳头周围视网膜神经纤维层厚度在12个月内无统计学显著变化,而黄斑中心厚度和乳突黄斑区脉络膜厚度显著降低。作者认为需更大样本、更长随访和更多注射次数的进一步研究。

要点

  • 玻璃体内雷珠单抗治疗12个月未显著改变神经节细胞复合体及视乳头周围视网膜神经纤维层厚度。
  • 黄斑中心厚度从基线至12个月进行性下降,第3个月降幅最大(P < 0.001)。
  • 乳突黄斑区鼻侧500、1000、1500 μm处脉络膜厚度显著降低(P < 0.001)。

核心结论

  • 玻璃体内雷珠单抗注射在1年随访中未影响视网膜神经纤维层和神经节细胞复合体厚度。
  • 治疗结束时乳突黄斑区脉络膜厚度和黄斑中心厚度显著降低。
  • 作者认为需更大样本、更长随访和更多注射次数的进一步研究。

研究设计与样本

  • 所有连续未经治疗的新生血管性年龄相关性黄斑变性患者接受三个月每月一次玻璃体内雷珠单抗负荷治疗,随后按需治疗方案再治疗12个月。
  • 主要结局为随访结束时神经节细胞复合体和视网膜神经纤维层的变化;次要结局为最佳矫正视力、黄斑中心厚度和脉络膜厚度的变化。
  • 脉络膜厚度在黄斑中心凹水平线和垂直线扫描上,分别于鼻侧、颞侧、上方和下方距中心凹500 μm、1000 μm和1500 μm处测量。
  • 共纳入24只眼。

主要发现

  • 神经节细胞复合体和视乳头周围视网膜神经纤维层厚度在12个月内无统计学显著变化(基线分别为55.6 ± 18.5 μm和81.9 ± 9.9 μm,第12个月分别为52.7 ± 19.3 μm和84.6 ± 15.5 μm,P > 0.05)。
  • 黄斑中心厚度从基线至第12个月进行性下降,第3个月降幅最大(P < 0.001)。
  • 距中心凹鼻侧500、1000和1500 μm处(对应乳突黄斑区)脉络膜厚度显著降低(从169.6 ± 45.3 μm降至153.9 ± 46.9 μm,P < 0.001)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 作者认为需更大样本、更长随访和更多注射次数的进一步研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To analyze the changes in ganglion cell complex and peripapillary retinal nerve fiber layer thickness, in central macular thickness and choroidal thickness on spectral domain optical coherence tomography in patients with neovascular age-related macular degeneration treated with intravitreal ranibizumab injections. METHODS: All consecutive patients with untreated neovascular age-related macular degeneration received loading phase of three monthly intravitreal ranibizumab, followed by retreatments on a pro re nata protocol for 12 months. PRIMARY OUTCOME: changes in ganglion cell complex and retinal nerve fiber layer at the end of follow-up. Secondary outcome: changes in best-corrected visual acuity, central macular thickness, and choroidal thickness at the end of follow-up. Choroidal thickness was measured at 500 μm, 1000 μm, and 1,500 μm intervals nasally, temporally, superiorly, and inferiorly to the fovea, respectively, on horizontal and vertical line scans centered on the fovea. RESULTS: Twenty-four eyes were included. Ganglion cell complex and peripapillary retinal nerve fiber layer thickness did not show statistically significant changes through 12 months (55.6 ± 18.5 and 81.9 ± 9.9 μm at baseline, 52.7 ± 19.3 and 84.6 ± 15.5 μm at month 12, P > 0.05). Central macular thickness showed progressive decrease from baseline to month 12, with maximum reduction at month 3 (P < 0.001). Statistically significant reduction in choroidal thickness was registered in the nasal 500, 1000, and 1,500 μm from the fovea, corresponding to the papillomacular region (from 169.6 ± 45.3 to 153.9 ± 46.9, P < 0.001). CONCLUSION: Intravitreal ranibizumab injections did not affect retinal nerve fiber layer and ganglion cell complex thickness in 1-year follow-up. Choroidal thickness in papillomacular area and central macular thickness was significantly reduced at the end of treatment. Further studies, with larger sample, longer follow-up, and greater number of injections, are warranted.

来源:Retina,查看原文。版权归原作者所有。

引用

  1. Zucchiatti I, Cicinelli MV, Parodi MB, et al. EFFECT OF INTRAVITREAL RANIBIZUMAB ON GANGLION CELL COMPLEX AND PERIPAPILLARY RETINAL NERVE FIBER LAYER IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION USING SPECTRAL DOMAIN OPTICAL COHERENCE TOMOGRAPHY. Retina. 2017. PMID: 28574419. doi:10.1097/IAE.0000000000001360

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。